Research Topics
| Antonella CastagnaSummaryAffiliation: San Raffaele Scientific Institute Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
AIDS 20:795-803. 2006..We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus...
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysisEnrico Girardi
Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L, Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy
BMC Health Serv Res 12:38. 2012..Identification of the determinants of access to investigational drugs is important to promote equity and scientific validity in clinical research. We aimed to analyze factors associated with the use of experimental antiretrovirals in Italy...- Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti
University of Brescia, Italy
BMC Infect Dis 11:23. 2011..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce... - The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patientsNicola Gianotti
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Italy
J Acquir Immune Defic Syndr 41:447-52. 2006..0001). The multivariable analysis showed that the 118I mutation (P = 0.04) was the only independent genotypic predictor of failing on a stavudine- containing highly active antiretroviral therapy... - Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimenNicola Gianotti
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
AIDS Res Hum Retroviruses 21:545-54. 2005..In highly PI-experienced patients, a PI-sparing regimen may lead to a reduction, no change, or increase in the number of PI mutations. The reduction is negligible in most cases... - Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavirNicola Gianotti
Clinic of Infectious Diseases, Universita Vita Salute San Raffaele, Milan, Italy
J Med Virol 78:1537-41. 2006..All of the GIQs were independent predictors of the 48-week virological response. The predictive value of the GIQ for lopinavir/ritonavir may vary depending on the algorithm used to score drug resistance... 
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Clin Virol 47:253-7. 2010..In HIV-1-infected patients harbouring the M184V mutation (M184V), lamivudine monotherapy leads to a smaller decrease in CD4 percentages (CD4%) than treatment interruption, possibly due to the reduced fitness of the mutated virus...- Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
New Microbiol 28:119-25. 2005..In conclusion, the number of ATV resistance mutations is the only correlate to virological response through 24 weeks of treatment with unboosted atazanavir 400 mg once daily... - Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapyNicola Gianotti
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
J Med Virol 72:181-6. 2004..A sustained virologic response to therapy resumption after treatment interruption can be achieved in the setting of virologic failure. An evaluation of clinical history may help to identify the patients who are more likely to respond... - Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapyAntonella Castagna
Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
Antivir Ther 15:165-75. 2010..The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined... - Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patientsVincenzo Spagnuolo
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Acquir Immune Defic Syndr 50:192-5. 2009..To evaluate changes in resistance to tipranavir/r (TPV/r) and darunavir/r (DRV/r) in patients who had failed a TPV/r-including regimen... - HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapyNicola Gianotti
Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy
J Med Virol 80:201-8. 2008..The de-selection of the 184V mutation predicts independently a reduction in the CD4+/CD8+ ratio... - Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failureFrancesca Cossarini
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Acquir Immune Defic Syndr 51:179-84. 2009..We evaluated long-term survival in multidrug-resistant patients recycling ENF after a previous failure... - Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patientsHamid Hasson
San Raffaele Scientific Institute, Clinic of Infectious Diseases, Via Stamira d Ancona 20, 20127 Milan, Italy
New Microbiol 29:223-30. 2006..The immunological response associated with ENF treatment is accompanied by a selective increase in IgE levels. Determination of IgE could be used in the monitoring ISRs associated with ENE.. - The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimenAntonella Castagna
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy
Antivir Ther 9:537-43. 2004..009) independently predicted a week-48 HIV-1 RNA level of <80 copies/ml. CONCLUSION: The LPV NIQ independently predicts virological responses to an LPV/RTV-containing regimen in highly treatment-experienced HIV-1-infected patients... - Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjectsMonica Guffanti
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Via Stamira d Ancona 20, 20127 Milan, Italy
Eur J Endocrinol 156:503-9. 2007..To evaluate the 24-week effects on glucose tolerance of switching from a protease inhibitor (PI)-based to an unboosted atazanavir-including regimen in highly pretreated HIV-1 infected subjects with metabolic alterations... - Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patientsHamid Hasson
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy
AIDS 18:123-7. 2004..Treatment with LPV/r can select for the 50 V mutation. In this setting, significant differences in the inference of the amprenavir phenotype from genotype were observed when using different algorithms... - In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patientsNicola Gianotti
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
New Microbiol 28:319-26. 2005..This suggests that the K103N mutation per se has little impact on viral fitness in vivo... - Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patientsNicola Gianotti
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy
AIDS 18:2205-8. 2004..After a median of 26 weeks of treatment, two patients (10%) selected the 65R mutation. These results support the hypothesis that NEM hinder the selection of this mutation... - Risk of type 2 diabetes among HIV-infected and healthy subjects in ItalyLaura Galli
Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
Eur J Epidemiol 27:657-65. 2012.... - Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLNicola Gianotti
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Antimicrob Chemother 67:213-7. 2012..It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining <1 HIV RNA copy/mL. We therefore investigated the effect of residual viraemia on virological rebound... - Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavirNicola Gianotti
Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy
AIDS 21:1648-51. 2007..The electrocardiographic monitoring of patients treated with atazanavir seems advisable... - Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcomeAntonella d'Arminio Monforte
Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
Antivir Ther 16:1103-12. 2011..To study the prevalence, predictors and outcome of late HIV diagnosis in the Icona cohort, according to the new European consensus definition of late diagnosis... - Immune recovery and T cell subset analysis during effective treatment with maravirocFrancesca Cossarini
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Antimicrob Chemother 67:2474-8. 2012..Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery... - Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravirFilippo Canducci
Vita Salute San Raffaele University, Laboratory of Virology and Microbiology, Milan, Italy
J Infect Dis 204:1811-5. 2011..However, viruses with mutation Q148R associated with secondary mutations and the combination Q148H+G140S were instead associated with a reduced level of susceptibility to dolutegravir in vitro... - Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutationsAlessandro Soria
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Med Virol 80:937-41. 2008..A complex interplay of viral and host factors, including the control of X4 viruses and proviral burden, may favor immune restoration with HIV neutralizing activity, despite persistent viremia... - Mortality of HIV-infected patients with or without cancer: comparison with the general population in ItalyLaura Galli
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
Antivir Ther 17:447-58. 2012..HAART has reduced mortality in HIV-infected patients; however, the risk of non-AIDS-related events has increased, including cancer. We compared mortality in HIV-infected patients with or without cancer with the general population in Italy... - Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignanciesVincenzo Spagnuolo
Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
Int J Cancer 130:2990-6. 2012..5% ± 14.5% vs. 40.0% ± 12.7%; log-rank test: p = 0.005). Despite the better cancer prognosis during the post-HAART era, the 10-year survival of HIV-infected subjects with an ADM or NADM is poor... - Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti
Department of Infectious Diseases, Vita/Salute University, San Raffaele Scientific Institute, Milan, Italy
AIDS 17:2669-71. 2003..Our preliminary results suggest that amprenavir and atazanavir could be coadministered and that amprenavir could be boosted by atazanavir without the need for ritonavir pharmaco-enhancement... - Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni
aDepartment of Infectious Diseases, San Raffaele Scientific Institute bUniversità Vita Salute San Raffaele cCardiometabolic and Clinical Trials Unit, Metabolic and Cardiovascular Division, Internal Medicine Department, San Raffaele Scientific Institute, Milan, Italy
AIDS 26:1837-40. 2012..A worsening glucose tolerance was observed in highly treatment-experienced HIV-infected patients receiving effective antiretroviral therapy after virological failure... - Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell countGiulia Marchetti
Department of Medicine, Surgery and Dentistry, Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Italy
AIDS 25:1385-94. 2011..We investigated the significance of microbial translocation measured on average 3 years after HIV seroconversion in driving disease progression in HIV untreated patients with high CD4(+) cell count... - No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapyNicola Gianotti
Department of Infectious Diseases, IRCCS San Raffaele, Milan, Italy
J Med Virol 83:391-8. 2011..145 per 0.1-unit increase, 95% CI=1.093-1.202, P<0.0001), and with earlier calendar years of resistance testing (overall effect: P=0.0007). In conclusion, no pol mutation is associated independently with the lack of immune recovery... - Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruptionCristina Mussini
Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
J Acquir Immune Defic Syndr 52:588-94. 2009..The extent of immune reconstitution following HAART resumption after 1 cycle of treatment interruption (TI) is not well known... - Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patientsSamuele E Burastero
Unit of Leukocyte Biology, San Raffaele Scientific Institute, Milan, Italy
J Clin Immunol 26:168-76. 2006..The hyper-IgE production in ENF-treated patients is associated with the in vitro induction of a type-2 phenotype in CD4 T cells... - Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 countsSilvia Nozza
San Raffaele Scientific Institute, Milan, Italy
J Antimicrob Chemother 67:1224-7. 2012..To investigate the value of tropism (determined by genotypic testing) to predict CD4 depletion in HIV-infected antiretroviral-naive patients with high CD4 counts... - Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesionChiara Elia
DIBIT, AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute, Via Olgettina, 58, 20132, Milan, Italy
J Leukoc Biol 82:1212-20. 2007..In conclusion, uPA inhibits HIV-1 replication in macrophages via up-regulation of cell adhesion to the substrate mediated by VN... - The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug developmentAntonella Castagna
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
Drugs 65:879-904. 2005.... - Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosisAntonella d'Arminio Monforte
Clinic of Infectious and Tropical Diseases, Dept of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, via A Di Rudinì 8 20142, Milan, Italy
Clin Infect Dis 49:612-22. 2009..We evaluated the correlation between the occurrence of different AIDS-defining illnesses (ADIs) and chronic HCV infection or HCV-related liver cirrhosis in a large Italian cohort of human immunodeficiency virus (HIV)-infected subjects... - Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individualsAnna Maria Brambilla
Infectious Diseases Clinic, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
AIDS 17:1993-5. 2003..Older men with HIV infection should be considered at higher risk of diabetes, and caution maybe warranted in the use of both indinavir and stavudine in these patients...